Advances in Low-Concentration Atropine and Optical Interventions for Myopia Control
DOI:
https://doi.org/10.71204/h4ject27Keywords:
Myopia Control, Low-concentration atropine, Orthokeratology, Defocus Incorporated Multiple Segments (DIMS), Combination TherapyAbstract
Myopia has become a global public health challenge, with its prevalence reaching epidemic proportions in recent decades, particularly in East Asian countries. This comprehensive review synthesizes recent evidence from clinical studies and meta-analyses to examine the efficacy and safety of low-concentration atropine and optical interventions for controlling myopia progression in children and adolescents. We show that low-concentration atropine (specifically 0.01%, 0.025%, and 0.05%) effectively slows myopia progression with a favorable safety profile. Furthermore, we evaluate optical interventions including orthokeratology (Ortho-K), Defocus Incorporated Multiple Segments (DIMS) spectacles, and peripheral progressive addition lenses. Emerging evidence suggests that combination therapy, integrating low-concentration atropine with an optical intervention, may yield superior effects compared to either modality alone. This review also discusses key issues such as treatment personalization, long-term adherence, and future research directions, providing evidence-based insights for clinicians managing childhood myopia.
References
Arumugam, B., & McBrien, N. A. (2012). Muscarinic antagonist control of myopia: Evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally induced axial myopia in the tree shrew. Investigative Ophthalmology & Visual Science, 53, 5827–5837. DOI: https://doi.org/10.1167/iovs.12-9943
Bullimore, M. A., & Brennan, N. A. (2019). Myopia control: Why each diopter matters. Optometry and Vision Science, 96, 463–465. DOI: https://doi.org/10.1097/OPX.0000000000001367
Chia, A., Lu, Q. S., & Tan, D. (2016). Five-year clinical trial on atropine for the treatment of myopia 2: Myopia control with atropine 0.01% eyedrops. Ophthalmology, 123, 391–399. DOI: https://doi.org/10.1016/j.ophtha.2015.07.004
Chua, W. H., Balakrishnan, V., Chan, Y. H., Tong, L., Ling, Y., Quah, B. L., & Tan, D. (2006). Atropine for the treatment of childhood myopia. Ophthalmology, 113, 2285–2291. DOI: https://doi.org/10.1016/j.ophtha.2006.05.062
Flitcroft, D. I. (2012). The complex interactions of retinal, optical and environmental factors in myopia aetiology. Progress in Retinal and Eye Research, 31, 622–660. DOI: https://doi.org/10.1016/j.preteyeres.2012.06.004
Holden, B. A., Fricke, T. R., Wilson, D. A., Jong, M., Naidoo, K. S., Sankaridurg, P., Wong, T. Y., Naduvilath, T. J., & Resnikoff, S. (2016). Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology, 123, 1036–1042. DOI: https://doi.org/10.1016/j.ophtha.2016.01.006
Jiang, Y., Zhu, Z., Tan, X., Kong, X., Zhong, H., Zhang, J., Xiong, R., Yuan, Y., Zeng, J., Morgan, I. G., & He, M. (2022). Effect of repeated low-level red-light therapy for myopia control in children: A multicenter randomized controlled trial. Ophthalmology, 129, 509–519. DOI: https://doi.org/10.1016/j.ophtha.2021.11.023
Lam, C. S. Y., Tang, W. C., Tse, D. Y., Lee, R. P. K., Chun, R. K. M., Hasegawa, K., Qi, H., Hatanaka, T., & To, C. H. (2020). Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: A 2-year randomised clinical trial. British Journal of Ophthalmology, 104, 363–368. DOI: https://doi.org/10.1136/bjophthalmol-2018-313739
Lee, S. H., Tsai, P. C., Chiu, Y. C., Wang, J. H., & Chiu, C. J. (2024). Myopia progression after cessation of atropine in children: A systematic review and meta-analysis. Frontiers in Pharmacology, 15, 1343698. DOI: https://doi.org/10.3389/fphar.2024.1343698
Perea-Romero, J., Signes-Soler, I., Badenes-Ribera, L., & Tauste, A. (2025). Efficacy of spectacle lenses specifically designed for myopia control: Systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 263, 909–924. DOI: https://doi.org/10.1007/s00417-024-06706-4
Sun, Y., Xu, F., Zhang, T., Liu, M., Wang, D., Chen, Y., & Liu, Q. (2015a). Correction: Orthokeratology to control myopia progression: A meta-analysis. PLoS ONE, 10, e0130646. DOI: https://doi.org/10.1371/journal.pone.0130646
Sun, Y., Xu, F., Zhang, T., Liu, M., Wang, D., Chen, Y., & Liu, Q. (2015b). Orthokeratology to control myopia progression: A meta-analysis. PLoS ONE, 10, e0124535. DOI: https://doi.org/10.1371/journal.pone.0124535
Tan, Q., Ng, A. L., Cheng, G. P., Woo, V. C., & Cho, P. (2019). Combined atropine with orthokeratology for myopia control: Study design and preliminary results. Current Eye Research, 44, 671–678. DOI: https://doi.org/10.1080/02713683.2019.1568501
Tedja, M. S., Wojciechowski, R., Hysi, P. G., Eriksson, N., Furlotte, N. A., et al. (2018). Genome-wide association meta-analysis highlights light-induced signaling as a driver for refractive error. Nature Genetics, 50, 834–848. DOI: https://doi.org/10.1038/s41588-018-0127-7
Wu, P. C., Chuang, M. N., Choi, J., Chen, H., Wu, G., Ohno-Matsui, K., Jonas, J. B., & Cheung, C. M. G. (2019). Update in myopia and treatment strategy of atropine use in myopia control. Eye, 33, 3–13. DOI: https://doi.org/10.1038/s41433-018-0139-7
Xu, S., Wang, M., Qu, Y., Wang, Y., Jiang, J., Zhou, F., Zhao, W., Zheng, B., Chen, W., Lei, X., Li, Z., Hu, Y., & Yang, X. (2025). Twice-daily administration improves the effectiveness of 0.01% atropine for controlling myopia in slowing axial elongation and refractive progression. Ophthalmic and Physiological Optics, 45, 1856–1866. DOI: https://doi.org/10.1111/opo.13558
Yam, J. C., Jiang, Y., Tang, S. M., Law, A. K. P., Chan, J. J., Wong, E., Ko, S. T., Young, A. L., Tham, C. C., Chen, L. J., & Pang, C. P. (2019). Low-concentration atropine for myopia progression (LAMP) study: A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology, 126, 113–124. DOI: https://doi.org/10.1016/j.ophtha.2018.05.029
Yam, J. C., Li, F. F., Zhang, X., Tang, S. M., Yip, B. H. K., Kam, K. W., Ko, S. T., Young, A. L., Tham, C. C., Chen, L. J., & Pang, C. P. (2020). Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: Phase 2 report. Ophthalmology, 127, 910–919. DOI: https://doi.org/10.1016/j.ophtha.2019.12.011
Yam, J. C., Zhang, X. J., Zaabaar, E., Wang, Y., Gao, Y., Zhang, Y., Li, X., Kam, K. W., Tang, F., Chu, W. K., Zhou, X., Zhang, W., He, X., Wu, P. C., Rose, K. A., Morgan, I., He, M., Ohno-Matsui, K., Jonas, J. B., Zhang, M., Tham, C. C., Chen, L. J., & Pang, C. P. (2025). Interventions to reduce incidence and progression of myopia in children and adults. Progress in Retinal and Eye Research, 109, 101410. DOI: https://doi.org/10.1016/j.preteyeres.2025.101410
Yam, J. C., Zhang, X. J., Zhang, Y., Wang, Y. M., Tang, S. M., Li, F. F., Kam, K. W., Ko, S. T., Yip, B. H. K., Young, A. L., Tham, C. C., Chen, L. J., & Pang, C. P. (2022). Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: Continued versus washout: Phase 3 report. Ophthalmology, 129, 308–321. DOI: https://doi.org/10.1016/j.ophtha.2021.10.002
Zhang, Y., & Wildsoet, C. F. (2015). RPE and choroid mechanisms underlying ocular growth and myopia. Progress in Molecular Biology and Translational Science, 134, 221–240. DOI: https://doi.org/10.1016/bs.pmbts.2015.06.014
Zheng, N. N., & Tan, K. W. (2022). The synergistic efficacy and safety of combined low-concentration atropine and orthokeratology for slowing the progression of myopia: A meta-analysis. Ophthalmic and Physiological Optics, 42, 1214–1226. DOI: https://doi.org/10.1111/opo.13029
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Weixing Xu, Yan Zhang (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in this journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are properly credited. Authors retain copyright of their work, and readers are free to copy, share, adapt, and build upon the material for any purpose, including commercial use, as long as appropriate attribution is given.
How to Cite
